Form 4: Amicus Therapeutics CEO Bradley Campbell Executes Stock Option and Sells Shares
SEC Form 4 Filing
Amicus Therapeutics' CEO, Bradley Campbell, exercised stock options and sold shares on November 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On November 1, 2024, Bradley L Campbell, the President and CEO of Amicus Therapeutics, exercised stock options to acquire 7,500 shares of common stock at a price of $8.61 per share.
- Simultaneously, Campbell sold 7,500 shares of Amicus Therapeutics common stock at a weighted average price of $11.4613, with prices ranging from $11.30 to $11.63.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on August 23, 2023.
- Following these transactions, Campbell directly owns 886,654 shares of Amicus Therapeutics common stock and 7,500 stock options.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports transactions. The use of a 10b5-1 plan suggests pre-planned and compliant activity.
Industry Context
This filing is a routine disclosure of insider transactions and provides transparency to the market regarding the trading activities of company executives. It is common for executives to utilize Rule 10b5-1 trading plans to manage their stock holdings and avoid accusations of insider trading.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the trades mitigates concerns about insider information.
Key Dates
| Date | Description |
|---|---|
| 2023-08-23 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-11-01 | Date of stock option exercise and share sale |
| 2025-01-02 | Expiration date of the stock options |
| 2024-11-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.